Prosthetic Joint InfectionMETAGENOSNCT06062251
Assessing the Performance of Shotgun Metagenomics in the Diagnosis of Complex Prosthetic Joint Infections
An observational study of Prosthetic Joint Infection, run by University Hospital, Brest at 6 sites in France.
Trial summary
The objectiveof this of a prospective, multicentre study is to evaluate the performance of shotgun metagenomics in the diagnosis of chronic Prosthetic joint infection (PJI) in comparison with the adapted MSIS diagnostic score.. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Prosthetic Joint Infection
- How many people
- 144 participants
- Where
- 6 sitesFrance
- Study dates
- 27 Feb 2024to 13 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with suspected chronic prosthetic joint infection
Who may be able to join
- Male or female ≥ 18 years
- Patients being considered for surgery for suspected chronic PJI (time between joint replacement surgery and patient inclusion > 3 months)
- Social security affiliation
- No objection to participating in the study
Who cannot join
- Suspicion or documentation (positive blood cultures) of acute bacteremia at time of inclusion
- Patients under guardianship or trusteeship
- Pregnant or breastfeeding woman
- Patient deprived of liberty by legal or administrative decision
- Patients in psychiatric care
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
France6 sites
Dr Rachel CHENOUARD
Angers
Brest university hospital
Brest, Brest, 29200
Dr Stéphane CORVEC
Nantes
Dr Chloé PLOUZEAU
Poitiers
Dr REISSIER Sophie
Rennes
Dr Marie-Frédérique LARTIGUE
Tours
About this study
Official title: Assessing the Performance of Shotgun Metagenomics in the Diagnosis of Complex Prosthetic Joint Infections (METAGENOS)
The objectiveof this of a prospective, multicentre study is to evaluate the performance of shotgun metagenomics in the diagnosis of chronic Prosthetic joint infection (PJI) in comparison with the adapted MSIS diagnostic score..
The main questions it aims to answer are:
- To evaluate the performance of shotgun metagenomics in the diagnosis of chronic PJI in comparison with culture.
- To describe the epidemiology of bacterial species responsible for chronic PJI in Western France and their potential resistance to antibiotics.
- Analyzing the diagnostic performance of shotgun culture and metagenomics as a function of potentially administered antibiotic treatments A total of 143 patients sampled will be included. Six intraoperative samples will be taken for each patient, as part of routine care. In addition to the standard preoperative check-up, an extra volume of blood will be taken for CRP measurement at inclusion.
Read the detailed description
Prosthetic joint infection (PJI) is one of the most serious and devastating complications of orthopaedic surgery, leading to a high risk of recurrence and disability, as well as increased mortality and management costs. Despite improvements in antibiotic prophylaxis procedures and surgical asepsis measures, the significant increase in the number of prostheses fitted worldwide has been accompanied by an increase in the number of infections. The infection rate has been estimated at between 1% and 2% after hip and knee arthroplasty.
Appropriate diagnosis and medical and surgical management of PJI are therefore essential to preserve and/or restore adequate motor function, minimise the risk of complications and prevent excessive morbidity. The microbiological diagnosis of PJI must be as early and exhaustive as possible in order to introduce rapid and effective antibiotic therapy and avoid the development of a biofilm (gangue around the material) or chronic infection (quiescent bacteria).
However, the diagnosis of PJI can be difficult to make in certain situations. Learned societies have established a definition of PJI and defined diagnostic scores combining clinical, biological, anatomopathological and cytological criteria. An initial definition was approved in 2011 by the Musculoskeletal Infection Society (MSIS). This definition was modified and subject to an international consensus review in 2013 (MSIS diagnostic score). In 2018, an international consensus meeting reviewed and adapted the MSIS score. This adapted score is more appropriate to current Medical Biology practices and to the non-accessibility of all diagnostic tests in laboratories (leucocyte esterase, alpha-defensin, ...).
In this definition of PJI, the positivity of 2 intra-operative samples to the same bacterial species is considered to be a major criterion. A wide range of bacteria can cause PJI: aerobic/anaerobic/intracellular/mycobacterial; somePJI can be polymicrobial. It is therefore essential to accurately identify these pathogens in order to administer appropriate antibiotic therapy and avoid chronicity of infection. Despite the optimisation of practices, culture of samples is negative in 5 to 30% of cases, despite the presence of diagnostic criteria for PJI. The most common causes are a lack of culture sensitivity, prior antibiotic administration and/or the presence of difficult or slow-growing pathogens. In these cases, intravenous broad-spectrum antibiotic therapy is administered, resulting in additional management costs, the occurrence of adverse treatment effects and the risk of acquiring resistance or intestinal dysbiosis.
In this context, "classic" molecular techniques are routinely used to overcome the limitations of culture for microbiological detection: bacterial-specific (including PCR targeting Staphylococcus aureus) or non-specific (bacterial universal PCR targeting the gene encoding 16S rDNA) (Figure 1). The latter approach was previously evaluated by the CRIOGO group (3Centre de Référence en Infections Ostéo-articulaires du Grand Ouest") with detection performance deemed disappointing in the context of PJI (sensitivity of 73.3%, specificity of 95.5%). Innovative molecular techniques for Next Generation Sequencing (NGS) are being developed, including shotgun metagenomics (sequencing of all the genetic material in a sample). Recent studies have evaluated the sensitivity of shotgun metagenomics in PJI, estimated at between 90.2% and 93.0% compared with bacterial culture and at around 95% compared with the MSIS diagnostic score.
However, these few recent studies evaluating shotgun metagenomics have only been carried out on a single sample per patient, which is insufficient according to the recommendations of the international and national consensuses on the management of PJI. In fact, four or even five intraoperative samples must be taken and analysed in microbiology to make the diagnosis of PJI. This high number of samples improves the sensitivity and completeness of bacterial detection and facilitates the interpretation of positive cultures for potentially contaminating skin bacteria (coagulase-negative Staphylococci, Cutibacterium acnes, etc.). To date, only one study has assessed the performance of shotgun metagenomics applied to several intraoperative samples per patient. Further studies are therefore needed to refine the performance of shotgun metagenomics in the context of PJI and to better assess the contribution of this costly technique, which requires considerable expertise to perform and interpret.
The setting up of a prospective, multicentre study in centres associated with the CRIOGO will make it possible to assess the performance of shotgun metagenomics in the management of chronic PJI. The performance of shotgun metagenomics will be assessed on the basis of four different samples per patient, in six centers specialising in the diagnosis of PJI, which makes the METAGENOS study unique compared with other studies. At the end of the project, the aim is to define the indications for using this innovative technique and to harmonise future regional practices.
- Conditions
- Prosthetic Joint Infection
- Keywords
- Prosthetic joint infection, microbiological diagnosis, shotgun metagenomics
What is being measured
The primary outcome is the main question the study is designed to answer.
PJI diagnosis
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by the adapted MSIS criteria (gold standard)MSIS diagnostic score (gold standard).
Measured: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Secondary outcomes (4)
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by culture
Measured: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Presence/absence of a bacterial species (by culture and/or shotgun metagenomics) in a patient sample considered infected according to the appropriate MSIS score
Measured: : from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Resistance/sensitivity to antibiotics tested
Measured: immediate post-operative period (usually within 3-15 days following surgery)
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by culture in case of presence/absence of antibiotic therapy the month before surgery
Measured: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2023
- Study start27 Feb 2024
- Primary completion13 Mar 2026
- Study completion13 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prosthetic Joint InfectionStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 144 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Rachel CHENOUARD, Dr, Principal investigator, Angers HUStéphane CORVEC, PhD, Principal investigator, Nantes HUChloé PLOUZEAU, Dr, Principal investigator, Poitier HUSophie REISSIER, Dr, Principal investigator, Rennes HUMarie-Frédérique LARTIGUE, Dr, Principal investigator, Tours HU
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06062251
- Sponsor's protocol ID
- 29BRC22.0208
- Acronym
- METAGENOS
- Status last verified
- Jun 2026
- First submitted
- 25 Sep 2023
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing the Performance of Shotgun Metagenomics in the Diagnosis of Complex Prosthetic Joint Infections (METAGENOS)
- ClinicalTrials.gov ID
- NCT06062251
- Acronym / sponsor ID
- METAGENOS / 29BRC22.0208
- Conditions
- Prosthetic Joint Infection
- Keywords
- Prosthetic joint infection, microbiological diagnosis, shotgun metagenomics
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 144 participants (actual)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 27 Feb 2024 (actual)
- Primary completion
- 13 Mar 2026 (actual)
- Study completion
- 13 Mar 2026 (actual)
- First posted
- 2 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectiveof this of a prospective, multicentre study is to evaluate the performance of shotgun metagenomics in the diagnosis of chronic Prosthetic joint infection (PJI) in comparison with the adapted MSIS diagnostic score..
The main questions it aims to answer are:
- To evaluate the performance of shotgun metagenomics in the diagnosis of chronic PJI in comparison with culture.
- To describe the epidemiology of bacterial species responsible for chronic PJI in Western France and their potential resistance to antibiotics.
- Analyzing the diagnostic performance of shotgun culture and metagenomics as a function of potentially administered antibiotic treatments A total of 143 patients sampled will be included. Six intraoperative samples will be taken for each patient, as part of routine care. In addition to the standard preoperative check-up, an extra volume of blood will be taken for CRP measurement at inclusion.
Detailed description
Prosthetic joint infection (PJI) is one of the most serious and devastating complications of orthopaedic surgery, leading to a high risk of recurrence and disability, as well as increased mortality and management costs. Despite improvements in antibiotic prophylaxis procedures and surgical asepsis measures, the significant increase in the number of prostheses fitted worldwide has been accompanied by an increase in the number of infections. The infection rate has been estimated at between 1% and 2% after hip and knee arthroplasty.
Appropriate diagnosis and medical and surgical management of PJI are therefore essential to preserve and/or restore adequate motor function, minimise the risk of complications and prevent excessive morbidity. The microbiological diagnosis of PJI must be as early and exhaustive as possible in order to introduce rapid and effective antibiotic therapy and avoid the development of a biofilm (gangue around the material) or chronic infection (quiescent bacteria).
However, the diagnosis of PJI can be difficult to make in certain situations. Learned societies have established a definition of PJI and defined diagnostic scores combining clinical, biological, anatomopathological and cytological criteria. An initial definition was approved in 2011 by the Musculoskeletal Infection Society (MSIS). This definition was modified and subject to an international consensus review in 2013 (MSIS diagnostic score). In 2018, an international consensus meeting reviewed and adapted the MSIS score. This adapted score is more appropriate to current Medical Biology practices and to the non-accessibility of all diagnostic tests in laboratories (leucocyte esterase, alpha-defensin, ...).
In this definition of PJI, the positivity of 2 intra-operative samples to the same bacterial species is considered to be a major criterion. A wide range of bacteria can cause PJI: aerobic/anaerobic/intracellular/mycobacterial; somePJI can be polymicrobial. It is therefore essential to accurately identify these pathogens in order to administer appropriate antibiotic therapy and avoid chronicity of infection. Despite the optimisation of practices, culture of samples is negative in 5 to 30% of cases, despite the presence of diagnostic criteria for PJI. The most common causes are a lack of culture sensitivity, prior antibiotic administration and/or the presence of difficult or slow-growing pathogens. In these cases, intravenous broad-spectrum antibiotic therapy is administered, resulting in additional management costs, the occurrence of adverse treatment effects and the risk of acquiring resistance or intestinal dysbiosis.
In this context, "classic" molecular techniques are routinely used to overcome the limitations of culture for microbiological detection: bacterial-specific (including PCR targeting Staphylococcus aureus) or non-specific (bacterial universal PCR targeting the gene encoding 16S rDNA) (Figure 1). The latter approach was previously evaluated by the CRIOGO group (3Centre de Référence en Infections Ostéo-articulaires du Grand Ouest") with detection performance deemed disappointing in the context of PJI (sensitivity of 73.3%, specificity of 95.5%). Innovative molecular techniques for Next Generation Sequencing (NGS) are being developed, including shotgun metagenomics (sequencing of all the genetic material in a sample). Recent studies have evaluated the sensitivity of shotgun metagenomics in PJI, estimated at between 90.2% and 93.0% compared with bacterial culture and at around 95% compared with the MSIS diagnostic score.
However, these few recent studies evaluating shotgun metagenomics have only been carried out on a single sample per patient, which is insufficient according to the recommendations of the international and national consensuses on the management of PJI. In fact, four or even five intraoperative samples must be taken and analysed in microbiology to make the diagnosis of PJI. This high number of samples improves the sensitivity and completeness of bacterial detection and facilitates the interpretation of positive cultures for potentially contaminating skin bacteria (coagulase-negative Staphylococci, Cutibacterium acnes, etc.). To date, only one study has assessed the performance of shotgun metagenomics applied to several intraoperative samples per patient. Further studies are therefore needed to refine the performance of shotgun metagenomics in the context of PJI and to better assess the contribution of this costly technique, which requires considerable expertise to perform and interpret.
The setting up of a prospective, multicentre study in centres associated with the CRIOGO will make it possible to assess the performance of shotgun metagenomics in the management of chronic PJI. The performance of shotgun metagenomics will be assessed on the basis of four different samples per patient, in six centers specialising in the diagnosis of PJI, which makes the METAGENOS study unique compared with other studies. At the end of the project, the aim is to define the indications for using this innovative technique and to harmonise future regional practices.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with suspected chronic prosthetic joint infection
Key inclusion criteria (4 listed)
- Male or female ≥ 18 years
- Patients being considered for surgery for suspected chronic PJI (time between joint replacement surgery and patient inclusion > 3 months)
- Social security affiliation
- No objection to participating in the study
Key exclusion criteria (5 listed)
- Suspicion or documentation (positive blood cultures) of acute bacteremia at time of inclusion
- Patients under guardianship or trusteeship
- Pregnant or breastfeeding woman
- Patient deprived of liberty by legal or administrative decision
- Patients in psychiatric care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
PJI diagnosis
Time frame: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by the adapted MSIS criteria (gold standard)MSIS diagnostic score (gold standard).
4 secondary outcomes
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by culture
Time frame: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Presence/absence of a bacterial species (by culture and/or shotgun metagenomics) in a patient sample considered infected according to the appropriate MSIS score
Time frame: : from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Resistance/sensitivity to antibiotics tested
Time frame: immediate post-operative period (usually within 3-15 days following surgery)
PJI diagnosis (positive/negative) obtained by shotgun metagenomics and by culture in case of presence/absence of antibiotic therapy the month before surgery
Time frame: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Related trials for Prosthetic Joint Infection
Recruiting
Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection
Prosthetic Joint Infection of Knee
RecruitingPhase 2
A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
Prosthetic Joint Infection (PJI)
RecruitingPhase 2/3
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Prosthetic-joint Infection
Not yet recruitingObservational study
oneKNEE - Prospective, Non-interventional, Multicenter PMCF-Study
Arthroplasty, Arthroplasty Replacement, Knee
Active, not recruiting
CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee
Revision Total Hip Arthroplasty (RTHA), Revision Total Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rachel CHENOUARD, Dr principal investigator
Angers HU
Stéphane CORVEC, PhD principal investigator
Nantes HU
Chloé PLOUZEAU, Dr principal investigator
Poitier HU
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prosthetic Joint Infection, run by University Hospital, Brest at 6 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PJI diagnosis (time frame: from samples taken during surgery. Shotgun metagenomics will be performed at the end of the inclusion of all patients, i.e. one year after the start of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.